Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Tumoral Versus Luminal Microbiome in Head and Neck Squamous Cell Carcinoma (MIC-VADS)

5. november 2026 opdateret af: Centre Hospitalier Sud Francilien

Head and neck squamous cell carcinoma (HNSCC), France's 5th most common cancer (15,000 annual cases), presents significant public health challenges due to high morbidity and functional/aesthetic sequelae from treatments (mutilating surgery, radiotherapy, chemotherapy). Major risk factors, tobacco and alcohol, create a chronic inflammatory environment promoting tumor development. The upper aerodigestive tract microbiome, influenced by these exposures and local alterations (necrosis, bleeding, ulcerations), is emerging as a potential factor in tumor progression, severity biomarker, or therapeutic target, though its exact role (cause or consequence) remains to be elucidated

Objectives:

  • Primary: Compare bacterial microbiome composition between tumor tissue, adjacent healthy mucosa, and pharyngeal secretions
  • Secondary:
  • Correlate microbiome diversity/composition with clinical and epidemiological characteristics
  • Identify microbiome variations by tumor stage, histology, and infiltration
  • Discover diagnostic/prognostic microbial markers
  • Analyze somatic variants (SNP/CNV) via whole-genome sequencing (WGS) and their association with microbiome profiles and clinical parameters

Study Design: Prospective, cross-sectional study with paired design (each patient serves as their own control to minimize genetic variation biases)

Methods:

  • Samples: Tumor, adjacent healthy tissue, and pharyngeal secretions (3 samples/patient)
  • Sequencing: Metagenomic sequencing (complete bacterial genomes) when biomass permits, or targeted 16S rRNA sequencing to identify dominant genera.
  • Pilot study: 20 patients to select the optimal technique and validate feasibility, particularly assessing DNA quantity in these low-biomass environments

Population: Adults with suspected HNSCC scheduled for panendoscopy

Exclusion criteria: Recent antibiotics/corticosteroids (12 weeks), immunosuppression (uncontrolled HIV, active hematologic malignancies, autoimmune diseases on immunosuppressants, organ/stem cell transplants, uncontrolled diabetes), immunomodulatory treatments (3 months), recurrence, pregnancy, non-French speakers, legal guardianship, or lack of social security.

Safety: No additional risks beyond standard panendoscopy.

Expected impact: This approach may pave the way for innovative diagnostic or therapeutic strategies based on microbiome modulation in HNSCC.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

120

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • France
      • Corbeil-Essonnes, France, Frankrig, 91100
        • Centre Hospitalier Sud Francilien
        • Kontakt:
        • Ledende efterforsker:
          • Renato TORRES, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Adult patient
  • Consultation in the ENT department for suspected squamous cell carcinoma of the upper aerodigestive tract scheduled for panendoscopy
  • Patient has provided consent to participate in the study and signed an informed consent form

Exclusion Criteria:

  • Antibiotic or corticosteroid therapy within 12 weeks prior to consultation

  • Conditions associated with immunosuppression:

    • Uncontrolled HIV infection (CD4 < 200 cells/µL) (permanent exclusion)
    • Hematologic malignancies currently under treatment or not in complete remission for <2 years
    • Autoimmune diseases under immunosuppressive treatment
    • Solid organ or stem cell transplant recipients (permanent exclusion)
    • Poorly controlled diabetes (HbA1c > 9%)
  • Immunomodulatory treatment within 3 months prior to consultation:

    • Immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1, anti-CTLA-4)
    • Biotherapy targeting the immune system (anti-TNF, anti-IL, calcineurin inhibitors, antimetabolites)
    • Recurrent upper aerodigestive tract cancer previously treated with surgery and/or radiochemotherapy
    • Pregnancy (confirmed prior to panendoscopy)
    • Patient who does not speak or understand French
    • Subject under guardianship or curatorship
    • Subject not affiliated with the national health insurance system

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Microbiome in head and neck squamous cell carcinoma Patients

Patients with suspected head and neck squamous cell carcinoma undergoing panendoscopy with additional biopsy sampling of tumor tissue, adjacent healthy mucosa, and pharyngeal secretions for microbiome analysis

Additional biopsies (beyond standard clinical practice) taken during panendoscopy to collect:

  • Tumor tissue
  • Adjacent healthy mucosa
  • Pharyngeal secretions

These samples are used for microbiome analysis.

head and neck squamous cell carcinoma Note: The panendoscopy itself is a standard clinical procedure, but the additional biopsies for research purposes represent the study-specific intervention.

Additional biopsies (beyond standard clinical practice) taken during panendoscopy to collect:

  • Tumor tissue
  • Adjacent healthy mucosa
  • Pharyngeal secretions

These samples are used for microbiome analysis.

head and neck squamous cell carcinoma Note: The panendoscopy itself is a standard clinical procedure, but the additional biopsies for research purposes represent the study-specific intervention.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
The difference in bacterial composition between the tumor, healthy mucosa, and hypopharyngeal secretions will be assessed
Tidsramme: at day 1
at day 1

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Differences in the tumor microbiome between subgroups defined by tumor stage, histological type, or infiltration, using differentiation tests
Tidsramme: at day 1
at day 1
Differential bacterial genera or strains between tumor, healthy, and pharyngeal microbiomes
Tidsramme: at day 1
at day 1
Correlations between tumor microbiome diversity and composition and clinical/epidemiological data
Tidsramme: at day 1

tumor microbiome diversity (by sequencing) tumor microbiome composition (by sequencing)

at day 1

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Béatrice SEGURENS, Phd, HDR

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. januar 2027

Primær færdiggørelse (Anslået)

28. februar 2028

Studieafslutning (Anslået)

28. februar 2028

Datoer for studieregistrering

Først indsendt

28. august 2026

Først indsendt, der opfyldte QC-kriterier

7. september 2026

Først opslået (Faktiske)

9. september 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2026-A00392-49
  • 2026/0003 (Anden identifikator: CHSF)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .